HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GMP Warnings Follow Thin Corrective Action Evidence, Reliance On Contract Manufacturers

This article was originally published in The Rose Sheet

Executive Summary

FDA warning letters to VitaPurity and Morhaim Pharmalab remind the supplement firms they can’t rely on contract manufacturers and suppliers to meet FDA’s GMP practices, and that statements of corrective actions without proof are inadequate.


Related Content

Total Nutrition Latest Own-Label Supplement Marketer Warned On GMP Violations
PharmaTech Recalls Highlight Supplement GMP Diligence For Marketers – CRN
Supplement GMP Warnings Pass 2015 Total, Own-Labeler Problems Climb





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts